Illumina, Inc. (ILMN)
$
99.27
+2.12 (2.14%)
Key metrics
Financial statements
Free cash flow per share
5.4654
Market cap
15.7 Billion
Price to sales ratio
3.6233
Debt to equity
1.1009
Current ratio
1.8562
Income quality
-1.0352
Average inventory
542 Million
ROE
-0.4649
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis, reflecting its robust operational framework. The earnings per share (EPS) is reported at -$7.69 indicating the company's profitability on a per-share basis, while the net total of other income and expenses is -$346,000,000.00 reflecting non-core financial activities. Operating expenses amount to $3,694,000,000.00 encompassing various operational costs incurred, and the total costs and expenses for the company are $3,772,000,000.00 reflecting its overall spending. Additionally, the weighted average number of shares outstanding is $159,000,000.00 highlighting the company's shareholder base and underscoring its financial health and stability. With a diverse range of products and services, Illumina serves a broad set of customers in genomic research centers, academic institutions, government laboratories, hospitals, and commercial entities in the pharmaceutical, biotechnology, and molecular diagnostics sectors. The company was incorporated in 1998 and is headquartered in San Diego, California, ensuring a strong presence in crucial markets. The stock is reasonably priced at $99.27 appealing to a broad range of investors looking for opportunities in the biotech field. Furthermore, the stock has a high average trading volume of $2,203,053.00 indicating strong liquidity and investor interest. With a mid-range market capitalization of $15,714,441,000.00 the company is a steady performer in the market. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape and driving advances in genetic analysis technologies. Additionally, it belongs to the Healthcare sector, which is experiencing rapid growth and innovation, positioning Illumina as a vital contributor to advancements in life sciences, oncology, and other emerging market segments.
Is Illumina, Inc. (ILMN) a good investment?
Investing in Illumina, Inc. (ILMN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Illumina, Inc. (ILMN)'s stock forecast?
Analysts predict Illumina, Inc. stock to fluctuate between $68.70 (low) and $156.66 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Illumina, Inc.'s market capitalization?
As of 2025-07-08, Illumina, Inc.'s market cap is $15,714,441,000, based on 158,300,000 outstanding shares.
How does Illumina, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Illumina, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Illumina, Inc. (ILMN) stock?
To buy Illumina, Inc. (ILMN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ILMN. Place an order (Market, Limit, etc.).
What is the best time to invest in Illumina, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Illumina, Inc. stock ever split?
Illumina, Inc.'s last stock split was 2:1 on 2008-09-23.
How did Illumina, Inc. perform in the last earnings report?
Revenue: $4,372,000,000 | EPS: -$7.69 | Growth: 4.63%.
Where can I find Illumina, Inc.'s investor relations reports?
Visit https://www.illumina.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Illumina, Inc.?
You can explore historical data from here
What is the all-time high and low for Illumina, Inc. stock?
All-time high: $555.77 (2021-02-12) | All-time low: $68.70 (2025-04-09).
What are the key trends affecting Illumina, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.
prnewswire.com
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO , June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. "The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024.
zacks.com
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
prnewswire.com
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases.
seekingalpha.com
Illumina, Inc. (NASDAQ:ILMN ) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 2:30 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participants Eve Burstein - Bernstein Eve Burstein All right. Thank you so much, everyone, for joining.
zacks.com
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
prnewswire.com
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illumina's IVD portfolio will also expand to offer Pillar oncoReveal® CDx, the newest panel to deliver critical companion diagnostic testing using the Illumina MiSeq™ Dx System SAN DIEGO , May 28, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more patients with cancer.
zacks.com
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
businesswire.com
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. Powered by SOMAmer® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum. Illumina Protein Prep 9.5K™ utilizes slow off-rate modified.
benzinga.com
Carl Icahn is making bold moves from the lab to the tarmac.
See all news
